Enzalutamide-resistant LNCaP ARF877L Mutation KI model

We have established an enzalutamide-resistant (LNCaP AR-F877L mutation) KI prostate cancer model to support the development of next-generation therapeutics.  An LNCaP AR-F877L KI cell line was shown to be resistant to enzalutamide, and in vivo animal validation studies demonstrated that enzalutamide was not efficacious to prevent tumor growth using this drug-resistant model.

Check out our comprehensive platform of drug-resistant animal models

Enzalutamide-resistant LNCAP AR F877L mutant KI model


← Return to Resources

Related Content

The efficacy of CAR-T therapy is substantially influenced by the tumor microenvironment. This is particularly evident when PD-L1 is activated...


WuXi AppTec scientists published a study in the open access archive ChemRxiv describing the discovery of highly selective, novel, heme...

← View all Oncology Resources
× peptide, amino acid

Contact An Expert Today!